IMMUNE NETWORK

  • 제8권2호
  • /
  • Pages.39-45
  • /
  • 2008
  • /
  • 1598-2629(pISSN)
  • /
  • 2092-6685(eISSN)
대한면역학회 (The Korean Association of Immunobiologists)
권호 표지

Sepsis Mortality in CIITA Deficient Mice is Associated with Excessive Release of High-mobility Group Box 1

  • Kim, Ji-Young (Department of Pathology, Hallym University College of Medicine) ;
  • Kim, Ju-Hyun (Department of Pathology, Hallym University College of Medicine) ;
  • Seo, Jae-Nam (Department of Pathology, Hallym University College of Medicine) ;
  • Oh, Kwon-Ik (Department of Pathology, Hallym University College of Medicine)
  • 발행 : 2008.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Down regulation of major histocompatibility complex class II transactivator (CIITA) has been identified as a major factor of immunosuppression in sepsis and the level of CIITA expression inversely correlates with the degree of severity. However, it has not been fully elucidated whether the lower expression of CIITA is a cause of disease process or a just associated sign. Here we determined whether the CIITA deficiency decreased survival rate using murine sepsis model. Methods: Major histocompatibility complex class II (MHC-II) deficient, CIITA deficient and wild type B6 mice were subjected to cecal ligation puncture (CLP) surgery. CIITA and recombination activation gene (RAG)-1 double deficient mice were generated to test the role of lymphocytes in CIITA-associated sepsis progression. Results: Sepsis mortality was enhanced in CIITA deficient mice, not by impaired bacterial clearance resulted from CD4 T cell depletion, but hyper-inflammatory response such as excessive release of a pro-inflammatory cytokine, high-mobility group box 1 (HMGB1). Conclusion: Our results demonstrate that CIITA deficiency affects the course of sepsis via the unexpected function of CIITA, regulation of cytokine release.

키워드

참고문헌

  1. Sessler CN, Shepherd W: New concepts in sepsis. Curr Opin Crit Care 8;465-472, 2002 https://doi.org/10.1097/00075198-200210000-00016
  2. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348;1546-1554, 2003 https://doi.org/10.1056/NEJMoa022139
  3. Annane D, Bellissant E, Cavaillon: Septic shock. Lancet 365;63-78, 2005 https://doi.org/10.1016/S0140-6736(04)17667-8
  4. Reinhart K, Karzai W: Anti-tumor necrosis factor therapy in sepsis: Update on clinical trials and lessons learned. Crit Care Med 29;S121-S125, 2001 https://doi.org/10.1097/00003246-200107001-00037
  5. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ: HMG-1 as a late mediator of endotoxon lethality in mice. Science 285;248-251, 1999 https://doi.org/10.1126/science.285.5425.248
  6. Lotze MT, Tracey KJ: High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol 5;331-342, 2005 https://doi.org/10.1038/nri1594
  7. Yang H, Tracey KJ: High mobility group box 1. Crit Care Med 33;S472-S474, 2005 https://doi.org/10.1097/01.CCM.0000187005.81616.A9
  8. Ulloa L, Messmer D: High-mobility group box 1 (HMGB1) protein: Friend and foe. Cytokine Growth Factor Rev 17;189-201, 2006 https://doi.org/10.1016/j.cytogfr.2006.01.003
  9. Qin S, Wang H, Yuan R, Li H, Ochani M, Ochani K, Rosas-Ballina M, Czura CJ, Huston JM, Miller E, Lin X, Sherry B, Kumar A, Larosa G, Newman W, Tracey KJ, Yang H: Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 203;1637-1642, 2006 https://doi.org/10.1084/jem.20052203
  10. Ting JP, Trowsdale J: Genetic expression of MHC class II expression. Cell 109;S21-S33, 2002 https://doi.org/10.1016/S0092-8674(02)00696-7
  11. dburger JM: Regulation of MHC class II gene expression by the class II transactivator. Nat Rev Immunol 5;793-806, 2005 https://doi.org/10.1038/nri1708
  12. Gourley T, Roys S, Lukacs NW, Kunkel SL, Flavell RA, Chang CH: A novel role for the major histocompatibility complex class II transactivator CIITA in the repression of IL-4 production. Immunity 10;377-386, 1999 https://doi.org/10.1016/S1074-7613(00)80037-0
  13. Zhu XS, Ting JP: A 36-amino-acid region of CIITA is an effective inhibitor of CBP: novel mechanism of gamma interferon-mediated suppression of collagen alpha(2)(I) and other promoters. Mol Cell Biol 21;7078-7088, 2001 https://doi.org/10.1128/MCB.21.20.7078-7088.2001
  14. Buttice G, Miller J, Wang L, Smith SD: Interferon-$\gamma$ induces major histocompatibility class II transactivator (CIITA), which mediates collagen repression and major histocompatibility class II activation by human aortic smooth muscle cells. Circ Res 98;472-479, 2006 https://doi.org/10.1161/01.RES.0000204725.46332.97
  15. Gourley TS, Patel DR, Nickerson K, Hong SC, Chang CH: Aberrant expression of Fas ligand in mice deficient for the MHC class II transactivator. J Immunol 168;4414-4419, 2002 https://doi.org/10.4049/jimmunol.168.9.4414
  16. Wong AW, Brickey WJ, Taxman DJ, van Deventer HW, Reed W, Gao JX, Zheng P, Liu Y, Li P, Blum JS, McKinnon KP, Ting JP: CIITA-regulated plexin-A1 affects T-cell-dendritic cell interactions. Nat Immunol 4;891-898, 2003 https://doi.org/10.1038/ni960
  17. Le Tulzo Y, Pangault C, Amiot L, Guilloux V, Tribut O, Arvieux C, Camus C, Fauchet R, Thomas R, Drenou B: Monocyte human leukocyte antigen-DR transcriptional downregulation by cortisol during septic shock. Am J Respir Crit Care Med 169;1144-1151, 2004 https://doi.org/10.1164/rccm.200309-1329OC
  18. Pachot A, Monneret G, Brion A, Venet F, Bohe J, Bienvenu J, Mougin B, Lepape A: Messenger RNA expression of major histocompatibility complex class II genes in whole blood from septic shock patients. Crit Care Med 33;31-38, 2005 https://doi.org/10.1097/01.CCM.0000150958.20209.A3
  19. Yan JJ, Jung JS, Lee JE, Lee J, Huh SO, Kim HS, Jung KC, Cho JY, Nam JS, Suh HW, Kim YH, Song DK: Therapeutic effects of lysophosphatidylcholine in experimental sepsis. Nat Med 10;161-167, 2004 https://doi.org/10.1038/nm989
  20. Buras JA, Holzmann B, Sitkovsky M: Animal mocel of sepsis: Setting the stage. Nat Rev Drug Discov 4;854-865, 2005 https://doi.org/10.1038/nrd1854
  21. Gourley TS, Chang CH: The class II transactivator prevents activation-induced cell death by inhibiting Fas ligand gene expression. J Immunol 166;2917-2921, 2001 https://doi.org/10.4049/jimmunol.166.5.2917
  22. Hotchkiss RS, Nicholson DW: Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 6;813-822, 2006 https://doi.org/10.1038/nri1943
  23. Fumeaux T, Pugin J: Role of interleukin-10 in the intracellular sequestration of human leukocyte antigen-DR in monocytes during septic shock. Am J Respir Crit Care Med 166;1475-1482, 2002 https://doi.org/10.1164/rccm.200203-217OC
  24. Marchant A, Bruyns C, Vandenabeele P, Ducarme M, Gerard C, Delvaux A, De Groote D, Abramowicz D, Velu T, Goldman M: Interleukin-10 controls interferon-$\gamma$ and tumor necrosis factor production during experimental endotoxemia. Eur J Immunol 24;1167-1171, 1994 https://doi.org/10.1002/eji.1830240524
  25. Standiford TJ, Strieter RM, Lukacs NW, Kunkel SL: Neutralization of IL-10 increases lethality in endotoxemia: cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J. Immunol. 155;2222-2229, 1995
  26. Sewnath ME, Olszyna DP, Birjmohun R, ten Kate FJ, Gouma DJ, van Der Poll T: IL-10-deficient mice demonstrate multiple organ failure and increased mortality during Escherichia coli peritonitis despite an accelerated bacterial clearance. J immunol 166;6323-6331, 2001 https://doi.org/10.4049/jimmunol.166.10.6323